Literature DB >> 23144343

A rare CFTR intronic mutation related to a mild CF disease in a 12-year-old girl.

Nadia Nathan1, Emmanuelle Girodon, Annick Clement, Harriet Corvol.   

Abstract

We report the case of a 12-year-old girl with an allergic bronchopulmonary aspergillosis (ABPA), intermediate sweat chloride tests and one cystic fibrosis (CF)-causing mutation, p.Phe508del. After extensive screening of the CF transmembrane regulator (CFTR) gene, she finally was found to carry a rare deep intronic mutation (c.872-1110_1113delGAAT), which confirmed the atypical mild CF disease. Although a classical steroid treatment did not allow the healing of the ABPA, an omalizumab therapy led to a long-term recovery. This case emphasises the need to search for rare CFTR gene mutations as far as possible when a CF disease is evocated. Moreover, it also highlights that although omalizumab is not yet recognised as a classical ABPA treatment in CF, it should be considered as an alternative therapy in steroid-resistant patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23144343      PMCID: PMC4543918          DOI: 10.1136/bcr-2012-006918

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  7 in total

1.  A case of allergic bronchopulmonary aspergillosis treated with omalizumab.

Authors:  I Sastre; J Blanco; H Mata; F García
Journal:  J Investig Allergol Clin Immunol       Date:  2012       Impact factor: 4.333

Review 2.  Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis.

Authors:  Richard B Moss
Journal:  Curr Opin Pulm Med       Date:  2010-11       Impact factor: 3.155

3.  Allergic bronchopulmonary aspergillosis and omalizumab.

Authors:  I Tillie-Leblond; P Germaud; C Leroyer; L Tétu; F Girard; G Devouassoux; J-P Grignet; A Prudhomme; D Dusser; B Wallaert
Journal:  Allergy       Date:  2011-04-26       Impact factor: 13.146

4.  Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.

Authors:  Patrick Lebecque; A Leonard; M Argaz; Véronique Godding; Charles Pilette
Journal:  BMJ Case Rep       Date:  2009-03-05

5.  A recurrent deep-intronic splicing CF mutation emphasizes the importance of mRNA studies in clinical practice.

Authors:  Catherine Costa; Virginie Pruliere-Escabasse; Alix de Becdelievre; Christine Gameiro; Lisa Golmard; Caroline Guittard; Laurence Bassinet; Thierry Bienvenu; Marie Des Georges; Ralph Epaud; Eric Bieth; Irina Giurgea; Abdel Aissat; Alexandre Hinzpeter; Bruno Costes; Pascale Fanen; Michel Goossens; Mireille Claustres; André Coste; Emmanuelle Girodon
Journal:  J Cyst Fibros       Date:  2011-07-23       Impact factor: 5.482

6.  Characterization of a disease-associated mutation affecting a putative splicing regulatory element in intron 6b of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Authors:  Valeria Faà; Federica Incani; Alessandra Meloni; Denise Corda; Maddalena Masala; A Maria Baffico; Manuela Seia; Antonio Cao; M Cristina Rosatelli
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

7.  CFTR genotypes in patients with normal or borderline sweat chloride levels.

Authors:  Delphine Feldmann; Remy Couderc; Marie-Pierre Audrezet; Claude Ferec; Thierry Bienvenu; Marie Desgeorges; Mireille Claustres; Hervé Mittre; Martine Blayau; Dominique Bozon; Marie-Claire Malinge; Nicole Monnier; Jean-Paul Bonnefont; Albert Iron; Eric Bieth; Viviane Dumur; Christine Clavel; Cécile Cazeneuve; Emmanuelle Girodon
Journal:  Hum Mutat       Date:  2003-10       Impact factor: 4.878

  7 in total
  2 in total

Review 1.  Fungal Pathogens in CF Airways: Leave or Treat?

Authors:  A Singh; A Ralhan; C Schwarz; D Hartl; A Hector
Journal:  Mycopathologia       Date:  2017-08-02       Impact factor: 2.574

Review 2.  Deep intronic mutations and human disease.

Authors:  Rita Vaz-Drago; Noélia Custódio; Maria Carmo-Fonseca
Journal:  Hum Genet       Date:  2017-05-12       Impact factor: 4.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.